

Medicinal active applications of Dibenzofuran derivatives


Mohammad Roshan Shoaib Savanur, Abhishek Kumar, Manoj Kumar,* Sonu Kumar*

Department of Chemistry/Hansraj College, University of Delhi

Submitted on: 25-May-2022, Accepted and Published on: 02-July-2022

Review

ABSTRACT



Dibenzofuran is an important heterocyclic compound and is an important part of various natural compounds. There are various medicinal compounds containing dibenzofurans, sold in the market to combat different human diseases and plant infections. Research on dibenzofuran is an advancing field in the medicinal science. Several compounds are under the clinical trials and are expected to be utilized in various treatments. This review article encompasses various advancements in the study of these dibenzo derivatives. The biological activity of these scaffolds hovering around cytotoxicity of the cells, bacterial infections, fungal infections, type-2 diabetes, platelet coagulation and in the effective skin treatment, has been discussed in the following article. The toxicology of the compound is also argued and selected biological applications are hereby discussed to make easier for the researchers to have a consolidated sight over the topic.

Keywords: Dibenzofuran Derivatives, Antibacterial Activities, Anti-cancer, Anti-malarial, Anti-fungal, Hyperglycemia, HIV-AIDS

INTRODUCTION

Dibenzofurans are heterotricyclic organic complexes with furan ring ortho-fused across 2,3- and 4,5- positions of the two benzene rings. The potent environmental pollutant mostly found in groundwater,¹ air² and also in the cigarette ash³ turns out to be widely used in the pharmaceutical industry on the other hand. The exploitation of this compound lets the scientists to develop several biologically active compounds with varied application in the medicinal chemistry. Most of the dibenzofurans and their derivatives can be isolated and extracted from the wide variety of natural sources ranging from slime molds to large trees.⁴⁻⁷ Whereas many scientists have put forth different synthetic methods ranging from the intermolecular C-C bonding and intramolecular C-O bond formation.⁸⁻¹¹ Cu-catalyzed deborylative ring contraction of dibenzoxaborins by Sumida

*et.al.*¹² Visible-light induced aromatization of 2-Vinyloxy arylalkynes by Chen and co-workers.¹³

Because of the varied chemical and biological properties, dibenzofurans are employed as the important complexes in variety of natural products^{14,15} and synthetic materials. Dbfs' uses have covered a vast field owing also to its weak biochemical stress response and high heat resistance.^{16,17} They provide strong backbone for the formation of decorated coordination compounds due to its rigidity.¹⁸ Whether in molecular probes¹⁹ or in the photochemistry for the production electrophosphorescent organic light emitting diodes,²⁰ Dbfs and their derivatives have participated vigorously across the time.

Dibenzofurans as the phytotoxins, anti-cancer agents and anti-bacterial agents have surpassed many pharmaceutical industry favourites. Therefore, the biological properties of such a compound should be even more altered to gain utmost advantages from such a privileged motif. This review encompasses several such advances happened down the line in the segments; anti-cancer, phytotoxic, anti-bacterial, anti-fungal and as anti-HIV agents,^{21,22} Cytotoxic^{23,24} and Antiplatelet Activities,²⁵ cotonefurans²⁶ in the medicinal chemistry, which gives an easy access of the proper knowledge to the researchers, to develop not only more bio-active compounds with increased biological activity but also varied applicable complexes.

*Corresponding Author: Dr. Sonu Kumar, and Dr. Manoj Kumar
Tel: +91 8826494724, +91 9873088062
Email: sonuchemhrc@gmail.com, (SK) manoj@hrc.du.ac.in (MK)



BIOLOGICAL ACTIVITY

The derivatives of dibenzofurans are widely used in medicinal chemistry. They show a lot of biological activities like anti-cancer activity, anti-bacterial, anti-fungal activity, anti-malarial, anti-allergic, anti-HIV-1 agent, anti-hyperglycemic, anti-platelet, anti-inflammatory.

stop the growth of cancer cells. The said dibenzo derivative proved to have efficient inhibiting ability at a relatively low concentration ($IC_{50} = 400$ nm). To add on its advantages, the authors also confirmed that it is not cytotoxic to CV-1 nontumor monkey kidney, whereas potentially cytotoxic ($IC_{50} = 2.5$ μ g/ml) to A549 non-small cell lung cancer cells. There has been many ongoing research carried out on this dibenzo derivative **1** owing




Figure 1. Biological active dibenzo furan containing anticancer agents.

ANTICANCER ACTIVITY

The notorious fatal disease characterized by the development of uncontrollably divisible abnormal cells, can easily destroy the normal body tissue. The most common disease of 2020 as per the WHO reports, is responsible for about 10 million deaths per annum. Right from the beginning, the search for more and more efficient methods, therapies and the drugs is being carried out to save millions of lives. Chemotherapy, gene therapy and protein therapeutics are some of the popular ones adapted.^{27,28} Every other research tends to improve the therapy and curb the difficulties of the people. Some dibenzo furan derivatives have proved to be cytotoxic, which even can be synthesized in simple processes. So, we hope that the further research on these complexes can led to some astonishing results.

Popolohuanone (E) **1** an oxidatively-dimerized arenarol derivative was isolated from the freeze-dried *Dysidea* sponge, collected at Pohnpei in the year 1993⁶. This was a breakthrough in the field of inhibitors of Topoisomerase-II; a target enzyme for most of the effective anti-cancer agents. T-II supports the DNA replication, which must be inhibited by the anti-cancer agents to

to its capability matching the currently usable anticancer agents for lung cancer like epipodophyllotoxins.

The *Scyphocephalum ochococa* is a medicinal tree belonging to western African tropical region. Tchouya and his co-workers revealed the presence of a dibenzofuran, within this plant which could be reason for its medicinal activity in the year 2021.²⁹ They extracted the yellow powdered form of the dibenzofuran and characterised it by using several techniques like IR, UV, MS, 1D- and 2-D NMR. From the investigations, they proved that the new dibenzofuran derivative **2** found in the stem bark of the plant has potential medicinal capability and also has anti-inflammatory behaviour. Thus, it could be used as an efficient chemotherapeutic agent.

Cellular slime molds were again used for the production of the secondary metabolites including polyketides. This time the fruiting bodies of *Dictyostelium discoideum* was utilized for the production of chlorinated dibenzofurans Pf-1 **3a** and Pf-2 **3b**.⁵ The compounds share similar structural formula with AB0022A,³⁰ thus all three were tested for their effects on cell growth in K562 leukemia cells, HeLa cervical carcinoma cells and mouse embryo fibroblast 3T3-L1 cells. To the better, the





Figure 2. Biological active dibenzo furan containing anticancer agents.

authors reported significant cell growth suppression by Pf-2 and AB0022A and also credited it to the presence of the free phenolic group adjacent to the carbonyl carbon.

make efficient drugs that also are less probable to undergo the resistance.

In the year 2002, Cortez and his co-workers reported their



a) i) HI O_3 , I_2 , EtOH, reflux, 30 min, 91%, ii) Cu, 240 °C, 6h, 81%; b) 57% HI aq. , reflux, 30 min, then CH_3I , K_2CO_3 , DMF, r.t., 3h, 12% (lit 37%³); c) 57% HI aq. , AcOH, reflux, 15h, 84%; d) (tert-Butyl) $_2\text{Si}(\text{OTf})_2$, 2,6-lutidine, DMF, 0 °C, 30 min, 67%; e) CH_3I , K_2CO_3 , DMF, r.t., 4h, 97%; f) tetra-n-butylammonium fluoride, THF, r.t., 30 min, 94%; g) caproyl chloride, pyridine, CH_2Cl_2 , 0 °C, 30 min, 66%; h) hv, benzene, r.t., 4h, 40%; i) $\text{Bn}(\text{Me})_3\text{N}^+\text{ICl}_4^-$, AcOH, r.t., 3h, 41%

Scheme 1 . Total synthesis of the antibacterial AB002A from the cellular slime mold.

Another series of dibenzofurans was reported for its cytotoxicity towards HeLa human epithelial carcinoma cell lines. Kaniwa and his fellow ones isolated a novel series called Kehokorins A-C **4** from the fruit bodies of the myxomycete, *Trichia favoginea* var. *persimilis*.⁴ Out of these, Kehokorin A was reported for its cytotoxicity against HeLa cells with an IC_{50} value of 1.5 $\mu\text{g/mL}$. The presence of rhamnose unit was credited for its cytotoxicity.

ANTIBACTERIAL ACTIVITY

The antibiotic resistance elements in the bacterial pathogens, has become the emerging and increasing problem for the researchers, policy makers and to the general public down these years. Many researchers have raised the topic to make new ways to curb the issues with pneumonia, tuberculosis, malaria and HIV-AIDS.³¹⁻³⁴ Discovery of the penicillin antibiotic in the late 1920s,³⁵ paved new way to the wound healing processes, but down the years its overuse has degraded that path due to the rise of drug resistant bacteria and super-bugs³⁶. Thus, the need is to

work on the extraction of few biologically important molecules from the leaves of the *Kielmeyera coriacea* (Guttiferae). The biphenyl aucuparin and xanthenes, found in the leaves was tested for their biological activity.³⁷ Phytochemical investigation of the dichloromethane extracts of *K. coriacea* leaves and stems has resulted in the isolation and identification of ten xanthenes, one biphenyl (aucuparin, **5a**) and two triterpenes. Among these compounds the researchers also reported a dibenzofuran derivative **5b** 1,3,7-trihydroxy-2-(3-methylbut-2-enyl)-xanthone showed antimicrobial activities against *Bacillus subtilis* with MIC values of 12.5mg/ml, respectively.

Sawada and co-workers isolated a novel antibacterial substance from the cellular slime mold *Dictyostelium purpureum* K1001 in the year 2000. This was the first time when the fruiting bodies of this slime mold was utilized for the production of a new compound. After many structure determination studies on the hydrogenated derivative of this compound, it was finally confirmed that, 1,9-dihydroxy-3,7-dimethoxy-2-hexanoyl-4,6,8-trichlorodibenzofuran is the structure required **Scheme 1**.³⁰ The compound was renamed as AB0022A **8** and was confirmed for





Figure 3. Biological active dibenzo furan containing antibacterial agents.

its biological activities involving inhibition of gram-positive bacteria *Bacillus subtilis* and *Staphylococcus aureus* (MIC = 0.39- 50 µg/ml).

Rhodomyrtoxin C **6**, a biologically active dibenzofuran was synthesized from *Pilidostigma glabrum* an Australian Myrataceae in the year 1983.³⁸ Shou et.al further studied about the anti-bacterial activity of the compound and reported that it shows activity against two different strains of *S. aureus* with MIC of 0.9 µM and 7.2 µM. The structurally similar Achyrofuran was also tested for its anti-bacterial activity.³⁹ When the compound was extracted from the aerial part of the plant and tested against the methicillin resistant and vancomycin-intermediate *S. aureus* strain NRS402, even the nanomolar concentrations, proved to be bacteriolytic by destroying 106 bacterial cells in 12hrs. Its anti-bacterial activity (MIC= 0.1 µM) was credited for its ability to compromise membrane impermeability of the cells.

Yet another antibacterial dibenzofuran was extracted from the *Myrtus communis* Linn; an evergreen sclerophyll shrub belonging to the Mediterranean flora, by Khan and co-workers in the year 2018⁴⁰. The structure of the phloroglucinol derivative **7** was elucidated by 1-D, 2-D NMR and electrospray ionisation-high resolution mass spectrometer and finally reported to be 1,1' - (1,3,7,9- tetrahydroxydibenzo [b,d] furan-2,8-diyl)- bis (ethan-1-one). This Dbf derivative turned out to be highly bacteriolytic against both gram positive *Staphylococcus aureus* and gram-negative *E. coli*. Thus, its in-vivo, in silico and synthetic studies have been a working topic for the researchers.

In the year 2017, Royo and his co-workers published their work on the synthesis of new symmetric polyoxygenated dibenzofurans. The synthetic protocol **Scheme-2**⁴¹ utilized phloroglucinol **18**, which was led to several reactions like monoacylation, iodination, Suzuki-Miyaura coupling, oxidative dimerization and regioselective cyclization to finally produce the required dibenzofurans **20** with 2-methylbutyryl moieties at C-4 and C-6. The authors reported the high anti-bacterial activity of these compounds with lipophilic chains at C-2 and C-8 against the gram-positive bacteria including multi-resistant *Staphylococcus aureus* NRS402 and methicillin -sensitive *Staphylococcus aureus* ATCC25923.



Scheme 3. Synthesis of 1-amino dibenzo [b,d]-furan derivatives using 1,3-dinitrophenol and iodophenol.

Shafi and co-workers synthesised a novel series of 1-amino dibenzo [b,d]-furan derivatives **23a-e** from the 1,3- dinitrophenol **21** and iodophenol **22** in the year 2019. After the structure elucidation of these compounds by ¹H and ¹³C NMR, the antifungal and antibacterial properties were examined⁴². The compound **23c** demonstrated potent biological activity against the *S. aureus* bacteria and the fungi *Candida albicans* **Scheme 3**. Thus, its further pharmacological applications are being researched.

ANTIFUNGAL ACTIVITY

Among the 300 known human infecting species of fungi, there are about 25, which are known to be very common in the environment.⁴³ Even though, the presence of antifungal therapies like polyenes, flucytosine, azoles and echinocandins have been effective to many fungal infections, but the parallel rise in immunocompromised population of the earth and the drug resistant fungi,⁴⁴ the invasive fungal infections are prevalent in the present times. Thus, there is need of more effective drugs, competitive strategies and efficient methods to counter the fungal infections.

In the year 2009, Shiu and co-workers published their work on the biological activity of the compounds extracted from the members of the genus *Hypericum*.⁴⁵ The extracted compounds were characterized by 1-D and 2D-NMR spectroscopy and mass spectroscopy. The new dibenzofuran **24** extracted from the *H. revolutum* ssp. *Revolutum* along with a pyranone, showed extensive medicinal properties. The authors had revealed that the mechanism of the action of this compound doesn't get affected by the multidrug resistant mechanisms of the most disease-causing bacteria strain; *Staphylococcus aureus*. The compound also proved to be acting as the major phytoalexins along with showing antifungal activity.

Further in the year 2014, Shi, Hu and co-workers published their work on the medicinal activity of a traditional Chinese plant; *Ligularia caloxantha*⁴⁶. The authors identified that the presence of benzofuran and dibenzofuran derivatives along with few triterpenes has the key role in the medicinal properties of the plant. Further they reported that the dibenzofuran derivatives present in the root parts of this mountainous plant, has the key role in the healing of cuts and wounds. The said compound **25** was also proved to give the antiscarid activity to this medicinal plant.

By studying the challenging mechanisms of the *Photinia davidiana* and the *Pyraantha* plants, Kokubun and the co-workers realized that these plants produced two different dibenzofurans as the phytoalexins to fight against the plant pathogens. The antifungal properties of the newly identified dibenzofurans, 7-methoxyeriobofuran and the 9-hydroxyeriobofuran was deeply discussed in their work, published in the year 1995.⁴⁷

The wood of *Pyrus communis* L. (perry pear trees) was subjected to the research and finally was determined to have the antifungal compounds α -pyrufuran and β -pyrufuran. The research was carried out in the year 1983 by Kemp and co-workers.⁴⁸ The Spectroscopic and chemical evidence showed that




Figure 4. Biological active dibenzo furan containing antifungal agents.

the compounds are 1,2,3,4-substituted trimethoxydibenzofuranols **26a-b**. These dibenzofurans were also analysed for their biological activity and was confirmed to have potent phytoalexin behaviour.

Two phytoalexins were synthesized from the diseased shoot and leaves of loquat (*Eriobotrya japonica*: Rosaceae) plant called aucuparin **27a-c** and eriobofuran **27d**. The researchers Watanabe and co-workers published their work in the year 1990,⁴⁹ which highlighted the antifungal activities of these compounds. Their research on these phytoalexins further led to the isolation of the two antifungal principles, 4'-methoxyaucuparin and raphiolepsin.

Research was carried out by Geza and co-workers in the year 1997, to investigate the Phytoalexin Production in an Apple Cultivar Resistant to *Venturia inaequalis*. With this research it was concluded that the major compound produced by scab-resistant cells in response to the challenge by the fungus, has been identified as the 2,4-methoxy-3-hydroxy-9-O- β -D-glucosyloxydibenzofuran by UV, mass spectrometry, ¹H-nuclear magnetic resonance (NMR), and ¹³C-NMR spectroscopy.⁵⁰ The dibenzoderivative (Malusfuran) **28** production within the plant, is one of the many components of the resistance principle of apples against *V. inaequalis*.

ANTIMALARIAL ACTIVITY

According to the WHO, Malaria is a life-threatening disease caused by the *Plasmodium* parasites. These parasites are carried into the human body via the infected female *Anopheles* mosquitoes. Out of the 5 different species of parasites, *Plasmodium falciparum* and *Plasmodium vivax* are considered to be the deadliest and unfortunately, dominant parasite species

across many countries.⁵⁰ Although there are appreciable number of drugs and insecticides being present in the market for the cure and prevention of the disease, but as the danger of parasites getting resistance towards them is hanging around the neck,⁵¹ the research of new and also environment friendly compounds is the need of hour. The below section specially involves some Dbf derivatives being utilized for the synthesis of anti-plasmodial agents.

Talontsi.et.al isolated two unusual dibenzofurans called Preussiafurans-A and B from the fungus *Preussia* sp, present in *Enantia Chlorantha* Oliv, along with other 6- known compounds in the year 2014.⁵² These Dbf derivatives were structurally elucidated by 1-D, 2-D NMR and HR-ESIMS. Upon the estimation, the authors reported that the Preussiafuran A **29a** with a carboxylic group at C-8 has more potent biological activity towards the chloroquine resistant strain NF₅₄ of malaria parasite *P.falciparum* with MIC₅₀ = 8.76 μ M. Moreover, the other substituent Preussiafuran B **29b** with a hydroxylated group, showed higher cytotoxicity on L6 cell lines.




Figure 5. Biological active dibenzo furan containing antimalarial agents.

An Endophytic fungus, *Xylaria* sp, was utilized by Tansuwan and fellow workers in 2007, to isolate 2-chloro-5-methoxy-3-

methyl cyclohexa-2,5-diene-1,4-dione **30** and Xylariaquinone A **31**.⁵³ The novel compounds had their structure confirmed by the spectroscopical data and single crystal X-ray data. Under the study by microculture radioisotope technique,⁵⁴ the authors reported that, both the compounds have in-vitro antiplasmodial activity against the multidrug resistant strain *Plasmodium falciparum* K1. However, when the IC₅₀ values of both the compounds 1.84 and 6.68 μ M were reported respectively, the lower activity of the dibenzo derivative was observed. With an addition of cytotoxic activity against the African green monkey kidney fibroblasts, both the compounds are further being studied for their efficient use.

ANTIALLERGIC ACTIVITY

In the year 2008, Dai and co-workers reported their work on the extraction of dibenzofuran derivatives from the fruit of *Pyracantha fortuneana*.⁵⁵ They isolated several dibenzofuran glycosides and fortuneanosides G-L **32a-f** from this fruit. These compounds were then subjected to the analysis for their various medicinal activities. The further reported that the Fortuneanosides G—J **32a-d** showed more potent tyrosinase-inhibitory activity than arbutin.




Figure 6. Biological active dibenzo furan containing antiallergic agents.

Impatiens balsamina L. a Chinese medicinal plant, known for its traditional use in the treatment of varied number of ailments like articular rheumatism, bruises, beriberi⁵⁶ and several types of dermatitis.⁵⁷ It is also known to possess antianaphylactic,⁵⁸⁻⁶⁰ antipruritic,⁶¹ and antihistamic⁶² activities. This magically medicinal plant was once again proved to have additional medicinal activity. Ishiguro et al. synthesised two novel dinaphthofurans, balsaminone A **33a** and balsaminone B **33b** from the pericarp of the fruit of this plant⁶³. On further evaluation, both the compounds showed potent antipruritic activity in mice. Thus, its anti-allergic properties are under further studies, whereas its anti-tumor activity⁶⁴ against MCF-7, HeLa, HCT-116 and HT-29 cell lines is already reported.

OTHER ACTIVITIES- ANTI-HIV-1 AGENT, ANTI-HYPERGLYCEMIC, ANTI-PLATELETS, ANTI - INFLAMMATORY

The first acquired immunodeficiency syndrome (AIDS) patient was found in the US in 1981. After that therapy for HIV-1 infection & AIDS has been used very rapidly.^{65,66} Within 10

years of the identification of the virus, the first drug, zidovudine was developed.^{67,68} After that a lot of drugs were developed for this virus.

Fan and co-workers carried out their study on the synthesis of human immunodeficiency virus-1 inhibiting in-vitro dibenzofurans, for the very first time in the year 2009.⁶⁹ Out of the 10 compounds synthesised by the team, the four compounds were proved to have potent anti-HIV activity on evaluation. The compounds with cyano group on the 2nd position and the presence of electron withdrawing groups like fluoro and nitro group, increased the potency of the dibenzofurans. Finally, the four dibenzofurans **34**, **35**, **36**, **37** were reported to have high activity with EC₅₀ values of 12.52, 15.32, 12.99 and 18.57 μ g/ml and TI values of >16.18, >13.10, >11.39 and >11.07 respectively.

The conversion of dietary starch and other complex carbohydrates into simple sugars by the gastrointestinal enzymes, is inhibited by the action of anti-hyperglycemic drugs. The blood sugar levels are nightmares for the diabetes-milletus patients. These drugs tend to control the same.





Figure 7. Biological active dibenzo furan containing anti-HIV-1, anti-hyperglycemic, anti-platelets, anti-inflammatory agents.

In the year 2001, Carney and co-workers published their work on the compounds derived from the *Achyrocline satureioides*; a South-American medicinal plant.⁷⁰ The bioassay guided fractionation led to the derivation of a new prenylated dibenzofuran called Achyrofuran **38**. This compound led to many changes in the world of non-insulin dependent diabetes mellitus. The active compound **38** was isolated from the components of the plant, after several processes including the LH-20 chromatography. The derived achyrofuran was proved to have significant antihyperglycemic activity in an in vivo type 2 diabetes mouse model.

The cyclooxygenase-1 (COX-1) enzyme acts as a platelet activator by generating thromboxane A₂.⁷¹ The platelet aggregation leads to thrombus formation which ultimately causes issues like coronary artery disease, cerebrovascular accidents and peripheral arterial disease.⁷² The anti-platelet therapy involves inhibition of COX-1 enzyme to prevent the platelet aggregation

in the blood vessels and blockage of blood flow to the body tissues.

The reaction of N-(2-methoxy-3-dibenzofuranyl)-2-chloroacetamide **39** with the substituted piperazine **40** derivatives led to the formation of a novel series of dibenzofuran-piperazine derivatives **41 a-m**. The research carried out by the authors Yurtas and co-workers in the year 2015, shed new light in the field of platelet activation and aggregation chemistry and finally leading towards more competent, efficient antiplatelet drugs with less chances for side effects like gastric erosion, agranulocytosis, neutropenia, thrombocytopenia, aplastic anemia and so on.⁷³ Out of many products of the reaction, the dibenzofuran with 2-furoyl **41m** substituent proved to be possessing high percentage inhibition as much as the standard drugs utilized in the similar purpose like aspirin, ridogrel, and dipyridamole on arachidonic acid induced platelet aggregation. The structure of the compound N-(2-methoxy-3-dibenzofuranyl)-2-[4-(2-furoyl) piperazin-1-yl] acetamide was characterized by ¹H NMR, ¹³C NMR, mass spectral data, elemental analysis and HPLC analysis.



Scheme 4: Total synthesis of dibenzofuran-piperazine series.

Four new dibenzofurans were isolated from the extract of the roots of *Rhaphiolepis indica* var. *tashiroi*.⁷ It is one of a variety of an evergreen shrub found in Taiwan, and also in many parts of Asia.⁷⁴ The root extract of the plant was tested positive for the anti-inflammatory activity. This was the alarming tone for the researchers to look for the chemical constituents of the plant. Out of a large number of dibenzofurans and biphenyls extracted from it, 2-hydroxy-3,4,6,9-tetramethoxydibenzofuran was determined to have potential anti-inflammatory activity. When compared with several other agents, this dibenzofuran derivative delivered more biological activity than the known anti-inflammatory agents like Eucidafuran and aucuparin.

CONCLUSION

In summary we can easily state that the use of dibenzofurans and their derivatives as the biologically active complexes in the medicinal field has grown extensively. The outstanding results of some experiments which are mentioned above, clearly give an idea of the enhancing demand for these complexes. The comparisons of these complexes with the other drugs and agents used in the similar field otherwise, give a positive point to these

complexes having similar or even better performance. Moreover, from the above data it can clearly be seen that, most of the dibenzofuran derivatives are either be isolated or derived from the natural products with least cost of synthesis, owing to their greener upper hand. The arising scope of Dbfs in the field of anticancer, anti-bacterial, anti-fungal, anti-hyperglycemic, anti-allergic and as anti-HIV agents can give more influencing results upon experimentation on these scaffolds. This review is directed to give better information for the synthesis of more accurate molecules with better biological properties and also to encourage development of better synthetic methods.

REFERENCES AND NOTES

1. T. Hofmann, A. Wendelborn. Colloid facilitated transport of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) to the groundwater at Ma Da Area, Vietnam. *Environmental Science and Pollution Research - International* **2007**, 14 (4), 223–224.
2. B.H. Aristizábal, C.M. Gonzalez, L. Morales, M. Abalos, E. Abad. Polychlorinated dibenzo-p-dioxin and dibenzofuran in urban air of an Andean city. *Chemosphere* **2011**, 85 (2), 170–178.
3. K.N. Thakore, H.M. Mehendale. Dibenzofuran. In *Encyclopedia of Toxicology*; Elsevier, **2014**; pp 67–69.
4. K. Kaniwa, T. Ohtsuki, Y. Yamamoto, M. Ishibashi. Kekokorins A–C, novel cytotoxic dibenzofurans isolated from the myxomycete *Trichia favoginea* var. *persimilis*. *Tetrahed. Lett.* **2006**, 47 (10), 1505–1508.
5. H. Kikuchi, Y. Kubohara, V.H. Nguyen, Y. Katou, Y. Oshima. Novel chlorinated dibenzofurans isolated from the cellular slime mold, *Polysphondylium filamentosum*, and their biological activities. *Bioorg. Med. Chem.* **2013**, 21 (15), 4628–4633.
6. J.R. Carney, P.J. Scheuer. Popolohuanone E, a topoisomerase-II inhibitor with selective lung tumor cytotoxicity from the Pohnpei sponge *Dysidea* sp. *Tetrahedron Lett.* **1993**, 34 (23), 3727–3730.
7. C.-H. Lin, H.-S. Chang, C.-H. Liao, et al. Anti-inflammatory Biphenyls and Dibenzofurans from *Rhaphiolepis indica*. *J. Natural Products* **2010**, 73 (10), 1628–1631.
8. J.-Q. Wang, R.G. Harvey. Synthesis of polycyclic xanthenes and furans via palladium-catalyzed cyclization of polycyclic aryltriflate esters. *Tetrahedron* **2002**, 58 (29), 5927–5931.
9. L.-C. Campeau, M. Parisien, A. Jean, K. Fagnou. Catalytic Direct Arylation with Aryl Chlorides, Bromides, and Iodides: Intramolecular Studies Leading to New Intermolecular Reactions. *J Am Chem Soc* **2006**, 128 (2), 581–590.
10. B. Liégault, D. Lee, M.P. Huestis, D.R. Stuart, K. Fagnou. Intramolecular Pd(II)-Catalyzed Oxidative Biaryl Synthesis Under Air: Reaction Development and Scope. *J. Org. Chem.* **2008**, 73 (13), 5022–5028.
11. C. Wang, I. Piel, F. Glorius. Palladium-Catalyzed Intramolecular Direct Arylation of Benzoic Acids by Tandem Decarboxylation/C–H Activation. *J Am Chem Soc* **2009**, 131 (12), 4194–4195.
12. Y. Sumida, R. Harada, T. Sumida, et al. Synthesis of Dibenzofurans by Cu-Catalyzed Deborylative Ring Contraction of Dibenzoxaborins. *Org. Lett.* **2020**, 22 (16), 6687–6691.
13. H. Chen, Y. Yan, N. Zhang, et al. Visible-Light-Induced Cyclization/Aromatization of 2-Vinyloxy Arylalkynes: Synthesis of Thio-Substituted Dibenzofuran Derivatives. *Org. Lett.* **2021**, 23 (2), 376–381.
14. M. Millot, A. Dieu, S. Tomasi. Dibenzofurans and derivatives from lichens and ascomycetes. *Natural Product Reports* **2016**, 33 (6), 801–811.
15. K. Ingólfssdóttir. Usnic acid. *Phytochemistry* **2002**, 61 (7), 729–736.
16. T. Kokubun. Four dibenzofuran phytoalexins from the sapwood of *Mespilus germanica*. *Phytochem.* **1995**, 39 (5), 1039–1042.
17. G. Collin, H. Höke. Benzofurans. In *Ullmann's Encyclopedia of Industrial Chemistry*; Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, **2007**.

18. D. Rosario-Amorin, E.N. Duesler, R.T. Paine, et al. Synthesis and Coordination Chemistry of Phosphine Oxide Decorated Dibenzofuran Platforms. *Inorg. Chem.* **2012**, 51 (12), 6667–6681.
19. F. Berndt, I. Ioffe, A.A. Granovsky, et al. 7-Amino-dibenzofuran-3-carboxylate: A new probe for femtosecond dynamic microsolvation studies of biomolecules. *J. Photochem. Photobiol. A: Chem.* **2012**, 234, 164–170.
20. P.A. Vecchi, A.B. Padmaperuma, H. Qiao, L.S. Sapochak, P.E. Burrows. A Dibenzofuran-Based Host Material for Blue Electrophosphorescence. *Org. Lett.* **2006**, 8 (19), 4211–4214.
21. J. Singh, B.S. Chhikara. Comparative global epidemiology of HIV infections and status of current progress in treatment. *Chem. Biol. Lett.* **2014**, 1 (1), 14–32.
22. B.S. Chhikara, B. Rathi. Organic molecular drugs designing for inhibition of cellular multiplication biocycle of virus for anti-HIV therapy development: A recent advances review. *Adv. Org. Chem. Lett.* **2015**, 2 (1), 1–14.
23. R. Kikumoto, Y. Tamao, K. Ohkubo, et al. Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N.alpha.-substituted L-arginine. *J. Med. Chem.* **1980**, 23 (12), 1293–1299.
24. D.W. Robertson, W.B. Laceyfield, W. Bloomquist, et al. Zatosetron, a potent, selective, and long-acting 5HT₃ receptor antagonist: synthesis and structure-activity relationships. *J. Med. Chem.* **1992**, 35 (2), 310–319.
25. T.-C. Wang, I.-L. Chen, D.-H. Kuo, C.-H. Liao. Synthesis and Cytotoxic and Antiplatelet Activities of Dibenzofuran- and Carbazole-Substituted Oximes. *Helvetica Chimica Acta* **2004**, 87 (4), 983–990.
26. C. Chizzali, L. Beerhues. Phytoalexins of the Pyrinae: Biphenyls and dibenzofurans. *Beilstein J. Org. Chem.* **2012**, 8, 613–620.
27. R. Zhang, T. Nie, Y. Fang, H. Huang, J. Wu. Poly(disulfide)s: From Synthesis to Drug Delivery. *Biomacromolecules* **2022**, 23 (1), 1–19.
28. Y. Zeng, J. Xiao, Y. Cong, et al. PEGylated Nanoscale Metal–Organic Frameworks for Targeted Cancer Imaging and Drug Delivery. *Bioconj. Chem.* **2021**, 32 (10), 2195–2204.
29. G.R. Feuya Tchouya, H. Foundikou, M. Mbiancha, et al. A new dibenzofuran derivative from the stem bark of *Scyphocephalum ochocoa* with anti-inflammatory and cytotoxic activities. *Natural Product Research* **2022**, 36 (6), 1503–1514.
30. T. Sawada, M. Aono, S. Asakawa, A. Ito, K. Awano. Structure Determination and Total Synthesis of a Novel Antibacterial Substance, AB0022A, Produced by a Cellular Slime Mold. *J. Antibiotics* **2000**, 53 (9), 959–966.
31. E.D. Brown, G.D. Wright. Antibacterial drug discovery in the resistance era. *Nature* **2016**, 529 (7586), 336–343.
32. S. NORRBY, C. NORD, R. FINCH. Lack of development of new antimicrobial drugs: a potential serious threat to public health. *Lancet Infectious Diseases* **2005**, 5 (2), 115–119.
33. H.W. Boucher, G.H. Talbot, J.S. Bradley, et al. Bad Bugs, No Drugs: No ESCAPE! An Update from the Infectious Diseases Society of America. *Clinical Infectious Diseases* **2009**, 48 (1), 1–12.
34. X. Li, S.M. Robinson, A. Gupta, et al. Functional Gold Nanoparticles as Potent Antimicrobial Agents against Multi-Drug-Resistant Bacteria. *ACS Nano* **2014**, 8 (10), 10682–10686.
35. E. Martens, A.L. Demain. The antibiotic resistance crisis, with a focus on the United States. *J. Antibiotics* **2017**, 70 (5), 520–526.
36. L.-Y. Hsu, A. Apisarnthanarak, E. Khan, et al. Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. *Clinical Microbiol. Rev.* **2017**, 30 (1), 1–22.
37. D.A.G. Cortez, B.A.A. Filho, C.V. Nakamura, et al. Antibacterial Activity of a Biphenyl and Xanthenes from *Kielmeyera coriacea*. *Pharmaceutical Biol.* **2002**, 40 (7), 485–489.
38. Q. Shou, L.K. Banbury, D.E. Renshaw, et al. Biologically Active Dibenzofurans from *Pilidiostigma glabrum*, an Endemic Australian Myrtaceae. *J. Natural Products* **2012**, 75 (9), 1612–1617.
39. C. Casero, A. Estévez-Braun, Á.G. Ravelo, et al. Achyrofuran is an antibacterial agent capable of killing methicillin-resistant vancomycin-intermediate *Staphylococcus aureus* in the nanomolar range. *Phytomedicine* **2013**, 20 (2), 133–138.
40. N. Khan, S. Rasool, S. Ali Khan, S. Bahadar Khan. A new antibacterial dibenzofuran-type phloroglucinol from *myrtus communis* linn. *Natural Product Research* **2020**, 34 (22), 3199–3204.
41. S. Oramas-Royo, K.D. Pantoja, Á. Amesty, et al. Synthesis and antibacterial activity of new symmetric polyoxygenated dibenzofurans. *Eur. J. Med. Chem.* **2017**, 141, 178–187.
42. R. Subaash, S.S. Kumar. Synthesis, characterization and antimicrobial activity of some novel 1-amino dibenzofuran derivatives. *Ind. J. Chem.-Sec. B*, **2021**, 60(7), 1022–1026.
43. J.R. Perfect. The antifungal pipeline: a reality check. *Nature Reviews Drug Discovery* **2017**, 16 (9), 603–616.
44. M.H. Miceli, J.A. Díaz, S.A. Lee. Emerging opportunistic yeast infections. *Lancet Inf. Diseases* **2011**, 11 (2), 142–151.
45. W.K.P. Shiu, S. Gibbons. Dibenzofuran and pyranone metabolites from *Hypericum revolutum* ssp. *revolutum* and *Hypericum choisianum*. *Phytochem.* **2009**, 70 (3), 403–406.
46. S.-Y. Shi, M.-H. Hu, D.-Y. Wu, et al. A new dibenzofuran and other constituents from *Ligularia caloxantha*, a chinese medicinal plant. *Natural Product Research* **2008**, 22 (7), 628–632.
47. T. Kokubun. Dibenzofuran phytoalexins from the sapwood tissue of *Photinia*, *Pyracantha* and *Crataegus* species. *Phytochemistry* **1995**, 39 (5), 1033–1037.
48. M.S. Kemp, R.S. Burden, R.S.T. Loeffler. Isolation, structure determination, and total synthesis of the dibenzofurans α - and β -pyrufuran, new phytoalexins from the wood of *Pyrus communis* L. *J. Chem. Soc., Perkin Trans. 1* **1983**, No. 0, 2267–2272.
49. K. Watanabe, S.M. Widyastuti, F. Nonaka. Two biphenyl compounds from *Rhaphiolepis umbellata* as its phytoalexin. *Agricultural and Biological Chemistry* **1990**, 54 (7), 1861–1862.
50. L. Yurttas, B.K. Çavuşoğlu, H.E. Temel, G.A. Çiftçi. Novel N-(2-Methoxydibenzofuran-3-yl)-2-aryloxyacetamide Derivatives: Synthesis and Biological Investigation. *Lett. Drug Design Discovery* **2021**, 18 (5), 471–479.
51. F.M. Talontsi, J.C. Matasyoh, R.M. Ngoumfo, R. Chepkorir. Mosquito larvicidal activity of alkaloids from *Zanthoxylum lemairei* against the malaria vector *Anopheles gambiae*. *Pesticide Biochemistry and Physiology* **2011**, 99 (1), 82–85.
52. F.M. Talontsi, M. Lamshöft, C. Douanla-Meli, S.F. Kouam, M. Spitteller. Antiplasmodial and Cytotoxic Dibenzofurans from *Preussia* sp. harboured in *Enantia chlorantha* Oliv. *Fitoterapia* **2014**, 93, 233–238.
53. S. Tansuwan, S. Pornpakakul, S. Roengsumran, et al. Antimalarial Benzquinones from an Endophytic Fungus, *Xylaria* sp. *J. Natural Products* **2007**, 70 (10), 1620–1623.
54. R.E. Desjardins, C.J. Canfield, J.D. Haynes, J.D. Chulay. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. *Antimicrobial Agents and Chemotherapy* **1979**, 16 (6), 710–718.
55. Y. Dai, G.-X. Zhou, H. Kurihara, W.-C. Ye, X.-S. Yao. Fortuneosides G-L, Dibenzofuran Glycosides from the Fruit of *Pyracantha fortuneana*. *Chem. Pharmaceutical Bulletin* **2008**, 56 (4), 439–442.
56. M. Jash, S. De, S. Pramanik, C. Chowdhury. Palladium(II)-Catalyzed Cascade Reactions of Ene–Ynes Tethered to Cyano/Aldehyde: Access to Naphtho[1,2-*b*]furans and Benzo[*g*]indoles. *J. Org. Chem.* **2019**, 84 (14), 8959–8975.
57. L. Liu, X. Ji, J. Dong, Y. Zhou, S.-F. Yin. Metal-Free Oxidative Annulation of 2-Naphthols with Terminal Alkynes Affording 2-Arylnaphtho[2,1-*b*]furans. *Org. Lett.* **2016**, 18 (13), 3138–3141.
58. A. Benzi, L. Bianchi, G. Giorgi, et al. An Easy Access to Furan-Fused Polyheterocyclic Systems. *Molecules* **2022**, 27 (10), 3147.
59. T. Zeng, S.-S. Zhou, J.-D. Xu, et al. Quality consistency evaluation of commercial *Impatiens Caulis* by integrating UPLC-QTOF-MS/MS chemical profiling and UPLC-DAD multi-components quantification approaches. *J. Pharmaceutical Biomed. Analysis* **2022**, 209, 114522.

60. A.H.F. Abdelwahab, S.A.H. Fekry. Synthesis, reactions and applications of naphthofurans: A review. *Eur. J. Chem.* **2021**, 12 (3), 340–359.
61. M. Chen, M.L. Vial, L. Gee, et al. The plant natural product 2-methoxy-1,4-naphthoquinone stimulates therapeutic neural repair properties of olfactory ensheathing cells. *Scientific Reports* **2020**, 10 (1), 951.
62. P. Vyas, B.D. Wadhvani, P. Khandelwal, H. Araya, Y. Fujimoto. Tectonaquinones A, B and C: three new naphthoquinone derivatives from the heartwood of *Tectona grandis*. *Natural Product Research* **2022**, 36 (7), 1707–1715.
63. K. Ishiguro, Y. Ohira, H. Oku. Antipruritic Dinaphthofuran-7,12-dione Derivatives from the Pericarp of *Impatiens balsamina*. *J. Natural Products* **1998**, 61 (9), 1126–1129.
64. Q. Li, W. Gao, J. Cao, et al. New cytotoxic compounds from flowers of *Lawsonia inermis* L. *Fitoterapia* **2014**, 94, 148–154.
65. K. Maeda, D. Das, T. Kobayakawa, H. Tamamura, H. Takeuchi. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. *Current Topics Med. Chem.* **2019**, 19 (18), 1621–1649.
66. R.C. Gallo, P.S. Sarin, E.P. Gelmann, et al. Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS). *Science (1979)* **1983**, 220 (4599), 865–867.
67. R. Yarchoan, Kent J. Weinhold, H.K. Lyerly, et al. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of htlv-iii/lav replication, to patients with aids or aids-related complex. *The Lancet* **1986**, 327 (8481), 575–580.
68. M.C. Graves, J.J. Lim, E.P. Heimer, R.A. Kramer. An 11-kDa form of human immunodeficiency virus protease expressed in *Escherichia coli* is sufficient for enzymatic activity. *Proceed. Nat. Acad. Sci.* **1988**, 85 (8), 2449–2453.
69. L.-L. Fan, W.-Q. Liu, H. Xu, et al. Anti HIV-1 Agents 2. Discovery of Dibenzofurans as New HIV-1 Inhibitors In Vitro. *Lett. Drug Design & Discovery* **2009**, 6 (3), 178–180.
70. J.R. Carney, J.M. Krenisky, R.T. Williamson, J. Luo. Achyrofurane, a New Antihyperglycemic Dibenzofuran from the South American Medicinal Plant *Achyrocline satureioides*. *J. Natural Products* **2002**, 65 (2), 203–205.
71. A.J.J. Wood, C. Patrono. Aspirin as an Antiplatelet Drug. *New England J. Medicine* **1994**, 330 (18), 1287–1294.
72. J. Thachil. Antiplatelet therapy – a summary for the general physicians. *Clinical Medicine* **2016**, 16 (2), 152–160.
73. L. Yurttas, U. Abu Mohsen, Y. Ozkan, et al. Synthesis and biological evaluation of some dibenzofuran-piperazine derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry* **2016**, 31 (6), 1177–1183.
74. K. Watanabe, S. Muslimah Widyastuti, F. Nonaka. Two Biphenyl Compounds from *Rhaphiolepis umbellata* as Its Phytoalexin. *Agricultural Biological Chem.* **1990**, 54 (7), 1861–1862.

AUTHORS BIOGRAPHIES

Mohammad Roshan Shoaib Savanur was born in Davanagere, Karnataka, India. He completed his high school from S.V.C. Pre-University College, Davanagere, Karnataka, India in 2017. He is currently pursuing BSc (Hons) in Chemistry from Hansraj College, University of Delhi, India. His scientific interest is in total synthesis of natural compounds, medicinal chemistry and bio-catalysis.



Abhishek Kumar was born in Hapur, Uttar Pradesh, India. He completed his Intermediate education at Star Al-Falah Inter College, Kithore, Meerut, India in 2016. He received a B.Sc. (Hons.) Chemistry degree from Hansraj College, University of Delhi, India in 2021. Currently, he is enrolled in M.Sc. Research in Chemical Science at the Queen Mary University of London, & will be completing his graduation in September 2023. Abhishek has a strong interest in medicinal chemistry, pharmaceutical chemistry, as well as in inorganic chemistry. His research interest is mainly focused on drug synthesis.



Dr. Manoj Kumar joined the Department of Chemistry, Hans Raj College, University of Delhi as Assistant Professor in the year 2010. He obtained his Master's Degree in Organic Chemistry and Doctorate in Chemistry from Bundelkhand University, Jhansi (U.P), India. He is the member of various Society like: Indian Society of Analytical Scientists (ISAS), Indian Science Congress Association, Green Chemistry Network Centre (GCNC) and Society for Technologically Advanced Materials (S.T.A.M.I), India. He is the recipient of various prestigious Awards including: Best Teaching Excellence Award of Delhi University, Best Innovative Idea Award for Research of Delhi University and Best Poster Award in International Conference organised by Ramjas College University of Delhi. His research interests include: Material Science, Heterocyclic Compound, Supramolecular Chemistry as well as in Computational Chemistry also.



Dr. Sonu Kumar was born in Uttar Pradesh, India. He completed his B.Sc. and M.Sc. in chemistry from Chaudhary Charan Singh University, Meerut, India in 2007 and 2009, respectively. He then received a Ph.D. degree in chemistry from Department of Chemistry University of Delhi in 2017, under the supervision of Prof. Akhilesh K. Verma.



He is currently working as an assistant professor in the Department of Chemistry, Hansraj College University of Delhi. His scientific interest is in towards one-pot transition metal-catalyzed synthesis of fused heterocycles.